Inicio/Comprar Péptidos en México/Retatrutide
98.7% HPLC
Retatrutide
Péptido

Retatrutide

★★★★★ 4.9 · In stock
$ 6,900.00$ 7,200.00 -4%
Presentation
5 mg $ 1,500.00
10 mg $ 2,800.00
30 mg $ 6,900.00
1

For Mercado Pago or bank transfer, send us a message.

Verifiable COA
Express shipping
Third-party tested
Description +
≈24%
Largest mean body-weight reduction among incretin compounds in published clinical research12 mg · 48 wk · Jastreboff, NEJM 2023
Purity ≥98.7% HPLCFormat Lyophilized powderVial 3 mlResearch use only

Dose response over time (research reference)

Percent change in body weight over 48 weeks by dose arm (Phase 2 trial, Jastreboff, NEJM 2023). Select an arm to highlight its curve and see its reduction over time:

0−5−10−15−20−25−30048121620243648Weeks since randomization% weight change−2.1−8.7%−16.3%−17.8%−21.7%−23.9%−24.2%
−8.7%body-weight change at 48 wk · 1 mg
−16.3%body-weight change at 48 wk · 4 mg (initial dose 2 mg)
−17.8%body-weight change at 48 wk · 4 mg (initial dose 4 mg)
−21.7%body-weight change at 48 wk · 8 mg (initial dose 2 mg)
−23.9%body-weight change at 48 wk · 8 mg (initial dose 4 mg)
−24.2%body-weight change at 48 wk · 12 mg (initial dose 2 mg)
Week 4 12 24 36 48
Δ weight −3.2% −5.2% −7.0% −7.8% −8.7%
Week 4 12 24 36 48
Δ weight −4.6% −9.0% −12.6% −14.6% −16.3%
Week 4 12 24 36 48
Δ weight −5.2% −10.4% −14.0% −16.2% −17.8%
Week 4 12 24 36 48
Δ weight −5.0% −11.8% −16.6% −19.6% −21.7%
Week 4 12 24 36 48
Δ weight −5.2% −13.2% −17.6% −21.0% −23.9%
Week 4 12 24 36 48
Δ weight −5.0% −12.2% −17.2% −21.2% −24.2%

Curves approximated from the published figure; 48-week values are the reported LS-mean endpoints.

Research reference only — data from a published clinical trial (Phase 2). Not dosing guidance for human use. MVLabs products are for in-vitro research use only.

Overview

Retatrutide is an investigational peptide currently being studied in metabolic research. It is designed as a triple receptor agonist, simultaneously interacting with three key pathways involved in metabolic regulation:

  • GLP-1 receptor (Glucagon-Like Peptide-1)
  • GIP receptor (Glucose-Dependent Insulinotropic Polypeptide)
  • Glucagon receptor

Because it engages all three pathways simultaneously, retatrutide is often referred to in scientific literature as a "triple agonist." This compound remains under clinical investigation and is not approved as a pharmaceutical product.

Research applications

  • Metabolic regulation and energy balance mechanisms
  • Glucose homeostasis and insulin secretion research
  • Appetite and satiety signaling pathway studies
  • Obesity and metabolic disorder research models
  • Triple receptor agonist pharmacology and receptor selectivity studies
  • Comparison with single and dual agonist GLP-1/GIP compounds

Research protocol reference

Dose levels referenced by the MVLabs peptide calculator, shown for research reference only:

Starting dose0.5 mg
MaintenanceUp to 8 mg
FrequencyOnce weekly

Triple GLP-1/GIP/glucagon agonist. Start low and titrate up every 2–4 weeks. Do not exceed 8 mg/week.

Research reference only — not dosing guidance for human use. Use the calculator for other vials or volumes.

Presentations & dosing: vial size varies by product. See the reconstitution guide in the Academy and use the calculator to convert your dose into exact units.

Open the calculator →

Comparative research data

In published clinical research, retatrutide produced the largest mean body-weight reduction among the leading incretin-based compounds. The figures below come from separate trials (not head-to-head):

Retatrutide12 mg · 48 wk
~24%
Tirzepatide15 mg · 72 wk
~22.5%
Semaglutide2.4 mg · 68 wk
~15%

Approximate mean body-weight reductions from published trials (Jastreboff et al., NEJM 2022–2023; Wilding et al., NEJM 2021), shown for research reference only — separate studies, not direct comparisons.

Handling & storage

Supplied as a lyophilized powder. Store at 2–8 °C on receipt; protect from heat, light and moisture, and avoid excessive agitation. If reconstitution is required for laboratory work, use sterile technique — bacteriostatic water, or 0.6% acetic acid for low-solubility peptides. Protocols vary by research application.

References

  1. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med 2023. nejm.org
  2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022. nejm.org
  3. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med 2021. nejm.org
Research use only. Research-grade, high-purity material (≥98.7% HPLC) supplied strictly for laboratory and analytical purposes. Not for human or animal consumption; not a drug or dietary supplement; not approved by the FDA, EMA or other agencies. To be handled only by qualified professionals in appropriate facilities, under all applicable laws. A certificate of analysis may be available on request.
Specifications +
Purity (HPLC)≥ 98.7%
FormLyophilized
CategoryPéptido
Storage-20 °C, no light
SKU8209021730931
Reconstitution +
Reconstitute with bacteriostatic water and use our reconstitution calculator to convert your target dose into syringe units.
Certificate (COA) +
Each batch includes a verifiable certificate of analysis at /verify using the product code.
Tool

Reconstitution & dosing calculator

Convert your target dose into syringe units for this compound, on its dedicated page.

Open calculator →
You may also need

Complete your protocol

Academy

Guides & articles

⚠ Solo para investigación (RUO). Compuesto liofilizado de grado investigación para uso in vitro únicamente. No aprobado para uso humano o veterinario. Venta a investigadores calificados. +18.